Physician profile
Dareen Daranee Siri
NPI 1730272998
$1,496,505.59
in general payments reported to CMS, 2019-2025
65 companies · $377K in 2025
The $377K reported for 2025 was more than what 99% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $179K · 2020: $109K · 2021: $135K · 2022: $258K · 2023: $203K · 2024: $235K · 2025: $377K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $357K · Consulting Fee: $284K · Travel and Lodging: $89K · Honoraria: $57K · Food and Beverage: $28K · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356,988.55 |
| Consulting Fee | $283,681.40 |
| Travel and Lodging | $88,582.53 |
| Honoraria | $57,176.45 |
| Food and Beverage | $28,175.49 |
| Education | $176.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $305,834.19 | 2019-2025 | Dupixent |
| Genzyme Corporation | $200,893.57 | 2019-2025 | |
| Abbvie INC. | $180,777.91 | 2019-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $157,756.19 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $117,419.07 | 2019-2025 | |
| Pharming Healthcare, INC. | $106,800.93 | 2019-2025 | Ruconest, Joenja |
| Adma Biomanufacturing LLC | $61,133.47 | 2021-2025 | |
| Incyte Corporation | $46,545.19 | 2022-2025 | Opzelura, Opzelura |
| Aimmune Therapeutics, INC. | $32,800.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $30,030.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $30,008.78 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Arcutis Biotherapeutics, INC. | $26,251.61 | 2023-2025 | Zoryve |
| Sanofi US Services INC. | $23,724.98 | 2025 | |
| Consortium of Independent Immunology Clinics, LLC | $21,673.61 | 2024-2025 | |
| Dermavant Sciences, INC. | $19,938.81 | 2024 | Tapinarof, Vtama |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $18,256.09 | 2024-2025 | Vtama |
| Blueprint Medicines Corporation | $17,397.40 | 2022-2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $16,728.39 | 2021-2024 | Ryaltris |
| Genentech USA, INC. | $14,796.24 | 2022-2025 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $10,137.51 | 2019 | |
| Pfizer INC. | $9,844.06 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $9,187.44 | 2025 | Dupixent |
| Ionis Pharmaceuticals, INC. | $8,718.35 | 2025 | Dawnzera, Donidalorsen |
| Biocryst Pharmaceuticals, INC. | $8,672.75 | 2020-2025 | Orladeyo |
| Biocryst US Sales Co., LLC | $4,343.68 | 2021-2024 | Orladeyo, Orladeyo |
| Grifols USA, LLC | $3,369.12 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $2,700.94 | 2020-2025 | Glassia, Hyqvia, Takhzyro |
| Gc Biopharma USA, INC. | $2,463.19 | 2025 | Alyglo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,091.51 | 2019-2021 | |
| Csl Behring | $1,302.76 | 2019-2025 | Hizentra, Haegarda |
| Shionogi INC | $1,011.06 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $750.00 | 2025 | Zoryve |
| Amgen INC. | $668.76 | 2023-2025 | Tezspire, Actimmune |
| Octapharma USA, INC. | $503.88 | 2020-2024 | Panzyga |
| Shire North American Group INC | $302.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $287.70 | 2019-2022 | |
| Circassia INC. | $175.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $165.03 | 2019-2025 | |
| Alk-Abello, INC | $151.99 | 2019-2025 | Odactra |
| Philips North America LLC | $137.95 | 2019-2022 | |
| Kaleo, INC. | $99.52 | 2019-2021 | |
| Horizon Therapeutics Plc | $83.28 | 2019-2022 | |
| Mylan Specialty L.P. | $67.55 | 2019-2022 | |
| Kyowa Kirin, INC. | $67.55 | 2025 | |
| Merck Sharp & Dohme LLC | $60.10 | 2022-2023 | |
| Leo Pharma INC. | $49.24 | 2023-2024 | Adbry |
| Bio Products Laboratory USA, INC. | $47.96 | 2022-2023 | Coagadex, Gammaplex |
| Sunovion Pharmaceuticals INC. | $45.18 | 2019 | |
| Kedrion Biopharma, INC. | $41.25 | 2023 | Koate, Kedrab, Gammaked |
| Phadia US INC. | $37.17 | 2022-2023 | Immunocap |
| United Therapeutics Corporation | $22.86 | 2022 | |
| Masimo Corporation | $21.65 | 2023 | Set and Rainbow Set |
| Itamar Medical INC | $20.75 | 2023 | Watchpatone |
| Ars Pharmaceuticals Operations, INC. | $19.70 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $18.62 | 2024 | Voquezna |
| Tersera Therapeutics LLC | $17.97 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.17 | 2021 | |
| Galderma Laboratories, L.P. | $15.57 | 2025 | Nemluvio |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,566.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$136,950.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dareen Siri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.